Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability
An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results for Alterity.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No News & Media currently available.